Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17197313 | 0.87 | CYP1A2 (0.56) | CYP1A2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4309752 | 0.85 | SMN1; SMN2 (0.54) | KDM4ENPC1RAB9AHSD17B10TP53 | |
| SCHEMBL25256914 | 0.85 | CA12 (0.61) | CYP1A2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL7369021 | 0.84 | KDM4E (0.52) | CYP1A2CYP2C9CYP2C19CYP3A4KDM4E | |
| SCHEMBL23716298 | 0.84 | CYP1A2 (0.45) | CYP1A2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL30744989 | 0.84 | HPGD (0.46) | CYP1A2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL27145832 | 0.84 | ACACB (0.47) | CYP1A2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL8324473 | 0.83 | NPC1 (0.47) | CYP1A2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL8324669 | 0.83 | PARP1 (0.49) | CYP1A2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5846153 | 0.81 | GAA (0.51) | CYP1A2CYP2D6CYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106188029-B | Two and ring class anaplastic lymphoma kinase inhibitor | 山东轩竹医药科技有限公司 | 2018-09-18 | — | — | CN | disclosed |
| US-20090258885-A1 | Diphenylmethane Derivatives as Inhibitors of Leukotriene Biosynthesis | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258885-A1 | Diphenylmethane Derivatives as Inhibitors of Leukotriene Biosynthesis | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258885-A1 | Diphenylmethane Derivatives as Inhibitors of Leukotriene Biosynthesis | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| WO-2008020306-A2 | ISOINDOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020306-A2 | ISOINDOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258885-A1 | Diphenylmethane Derivatives as Inhibitors of Leukotriene Biosynthesis | LTC4S, LTA4H, ALOX5 | CYP1A2 670/4885CYP2D6 756/4885CYP2C9 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.